A large array of clinically unique disease-modifying therapies (DMTs) is approved for the treatment of multiple sclerosis (MS) in the United States. Competition in this crowded market has intensified with the launch of Ocrevus and Copaxone generics, making treatment choices more complex. The U.S. market is expected to become even more competitive with the potential launch of second-generation follow-on DMTs (e.g., Novartis’s siponimod, Celgene’s ozanimod, Janssen/Acetlion’s ponesimod, Biogen’s BIIB-098) that are poised to offer incremental clinical gains over the next several years, coupled with the entry of oral generics. These evolving dynamics make brand differentiation as well as understanding of drug prescribing patterns and key patient characteristics, including financial burden, ever more critical for current and future players.
Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive Real World Data (RWD) repository.